NCT01572545COMPLETEDanonymous

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial

Sponsor

Source record

Aristotle University Of Thessaloniki

Phase

Source record

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Serum sclerostin levels in postmenopausal women with low bone mass

Indication / condition

AI-normalized

Postmenopausal Osteoporosis

Intervention

Source record

Denosumab, Zoledronic acid

Source & freshness

Source record

NCT ID

NCT01572545

Original source

ClinicalTrials.gov

Source last updated

Jan 17, 2013

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01572545

Title

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial

Sponsor

Aristotle University Of Thessaloniki

Status

COMPLETED

Phase

Condition raw

Postmenopausal Osteoporosis

Condition normalized

Postmenopausal Osteoporosis

Modality raw

Postmenopausal Osteoporosis

Modality normalized

monoclonal antibody

Target raw

Serum sclerostin levels in postmenopausal women with low bone mass

Target normalized

Serum sclerostin levels in postmenopausal women with low bone mass

Interventions

Denosumab, Zoledronic acid

Public preview

Source record

This completed clinical trial compared the effects of Zoledronic Acid and Denosumab on serum sclerostin levels, a key biomarker in bone metabolism, in postmenopausal women with low bone mass. The study aimed to provide insights into the efficacy of these two leading osteoporosis treatments.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01572545

Status

COMPLETED

Phase

Sponsor

Aristotle University Of Thessaloniki

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 17, 2013

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01572545

Indication

Postmenopausal Osteoporosis

Modality

monoclonal antibody

Target

Serum sclerostin levels in postmenopausal women with low bone mass

Intervention

Denosumab, Zoledronic acid

Source record